Novartis

Key TakeawaysBioAge Labs partners with Novartis to discover drug targets for age-related diseases. Collaboration includes $20M upfront funding and up to $530M in...

Key TakeawaysKisqali enhances disease-free survival across multiple patient demographics. The combination therapy is effective regardless of nodal status, expanding its therapeutic reach. Safety...

Key TakeawaysNearly double the number of eligible early breast cancer patients in Europe Significant reduction in recurrence risk enhances long-term survival prospects Kisqali's...

Key TakeawaysAsciminib demonstrates sustained efficacy and safety in long-term CML-CP treatment. Kisqali’s extended analysis highlights its effectiveness in reducing breast cancer recurrence. Novartis’s...

Key TakeawaysNovartis’ acquisition introduces advanced AAV-based platforms that could accelerate the development of treatments for DMD, FSHD, and DM1. The DELIVER platform’s targeted...

Key TakeawaysNovartis ranks first, with GSK following closely, yet overall progress in access to essential medicines remains stagnant. Only 43% of clinical trials...

Key TakeawaysScemblix offers a new treatment option for newly diagnosed and previously treated Ph+ CML-CP patients. The drug demonstrates superior efficacy compared to...

Key TakeawaysFabhalta targets the underlying cause of C3G, offering an innovative and effective treatment option. The drug demonstrates early and sustained improvements in...

Key Takeaways Novartis' Kisqali® (ribociclib) has received a positive opinion from the European Medicines Agency's (EMA) CHMP, marking it as a potential treatment for hormone...

Key TakeawaysThe FDA has approved ribociclib (Kisqali) with an aromatase inhibitor and the ribociclib and letrozole co-pack for high-risk early breast cancer. The...

Key TakeawaysKisqali® (ribociclib) with endocrine therapy reduced the risk of breast cancer recurrence by 28.5% in patients with HR+/HER2- early breast cancer. Invasive...

Key TakeawaysLindy Biosciences and Novartis have entered a strategic partnership that leverages Lindy's microglassification technology, enabling the transition of biologic drugs from intravenous...

Key TakeawaysThe Phase III V-MONO study demonstrated that Leqvio® significantly reduced LDL-C levels in patients at low or moderate risk of ASCVD, outperforming...

Key Takeaways:Novartis' Leqvio® (inclisiran) has shown significant LDL-C lowering as monotherapy in patients at low to moderate ASCVD risk. The Phase III V-MONO...

Key Takeaways:Novartis partners with Versant Ventures to form Borealis Biosciences, focusing on developing xRNA-based medicines for kidney diseases. This deal involves Novartis' divestment...